JPRN-jRCT2031220537已完成1 期
A clinical pharmacology, single topically dose study to evaluate the safety and pharmacokinetics of M605110 short contact therapy in patients with acne vulgaris
Tomoyuki Nishiura0 个研究点目标入组 16 人开始时间: 2022年12月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 49age old（—）
- 性别
- Male
入选标准
- •Patients with acne vulgaris who are 18 to 49 years of age at the time of informed consent
排除标准
- •(1)Patients with a history or merger of cardiac, hepatic, plumonary, renal, hematologic, or other diseases considered inappropriate for paticipation in the clinical study
- •(2)Patients with inflamed cysts/induration
- •(3) Patients with diseases other than acne vulgaris at the planned application site of study drug
- •(4)Patients who are judged to be clinically abnormal by the principal (sub) investigator based on clinical tests, vital signs, and electrocardiogram
- •(5)Patients who are judged to be unsuitable as subject by the principal (sub) investigator
研究者
相似试验
招募中
不适用
A single-dose safety and pharmacokinetic study of ReliBeta® ((Interferon beta-1a 2x30 micrograms pre-filled syringe) in healthy adults.CTRI/2018/02/011802Reliance Life Sciences Pvt Ltd20
已完成
1 期
Comparative assessment of the absorption of a generic formulation of Inhaled Insulin against the innovators Humalog KwikPen for injection and the AFREZZA Inhalation Powder Cartridge conducted under fasting conditions in healthy male and female volunteersPharmacokinetic and pharmacodynamic study conducted in healthy volunteers comparing three formulations of Insulin with no health condition or problem studied. Insulin is a medicine that is used to lower blood glucose.Pharmacokinetic and pharmacodynamic study conducted in healthy volunteers comparing three formulations of Insulin with no health condition or problem studied.Insulin is a medicine that is used to lower blood glucose.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12615001100583Zenith Technology Corp Ltd21
已完成
1 期
Comparative assessment of the absorption of a generic formulation of 5 mg bis [(E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2- [methyl(methylsulfonyl) amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt orally disintegrated tablet (ODT) against the innovator 40 mg bis [(E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2- [methyl(methylsulfonyl) amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt oral tablet conducted under fasting conditions in healthy volunteers.bis [(E)-7-[4-(4-fluorophenyl)- 6-isopropyl-2- [methyl(methylsulfonyl) amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt is indicated in patients with no hyperchloesterolaemia as an adjunct to diet when the response to diet and exercise is inadequate.Cardiovascular - Other cardiovascular diseasesACTRN12621001409864Zenith Technology Corporation Limited16
已完成
不适用
A single-center, open-label, single oral dose study to investigate the absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetics of EMA401 after a single dose of [14C]EMA401 in healthy male subjectsNL-OMON44485ovartis Pharma AG6
已完成
1 期
Comparative assessment of the absorption of a generic formulation of 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet against the innovator 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet conducted under fasting conditions in healthy volunteers.ACTRN12620000327987Zenith Technology Corporation Limited26